According to the eagle-eyed sleuths at Whale Alert, this little maneuver hasn’t exactly slipped under the radar. The market’s abuzz with speculation, old bean, and not a soul can quite put their finger on what Ripple’s up to. Is it a bullish gambit, or merely a spot of housekeeping? The jury’s still out, what?
Picture this: May to November 2025, Bitcoin’s trading at a cool $92,838. Butterfield, armed with his Wyckoff wand, maps out a distribution so textbook, it’s like Shakespeare wrote it. The summer rally hits a Buying Climax (BC) just north of $123,000-cue the confetti! 🎉 But then, an Automatic Reaction (AR) swoops in, setting support at $112,000. A Secondary Test (ST) tries to revisit the glory days, but that white resistance line at $123,000 says, “Not today, buddy.” 🚧
The integration, which quietly debuted in December 2024 (as if it were a shy debutante at a ball), allows UK and EEA customers to send USDC, USDT, and POL with the speed of a Cossack’s horse and the cost of a single samovar’s worth of tea. The result? Over $690 million in transactions, proving that sometimes, silence speaks louder than words. 🤫💸
Ah, the marvels of the modern world! Grab, the super-app so grand it makes other apps look like mere crumbs, has joined forces with StraitsX, a stablecoin sorcerer from the land of Singapore. Together, they plot to weave a Web3 payments system so slick, it’ll make traditional banking look like a snail on a Sunday stroll. 🐌
The timing and the scale have raised urgent questions about political responsibility, judicial oversight, and the fate of funds tied to one of Argentina’s most contentious crypto investigations. 🧠
According to a November 14, 2025 SEC filing, 5AM Venture Management, LLC, liquidated its position in Viking Therapeutics (VKTX 0.68%) as of Q3 2025. The fund sold its entire holding of 189,593 shares over the quarter, reducing its stake from 1.9% of assets under management to zero. The estimated value of the transaction was approximately $5.02 million based on the average share price for the quarter.
Lo, Standard Chartered’s Geoffrey Kendrick, that most patient of sages, beholds the carnage of Tuesday’s midnight plunge and chuckles, as if witnessing the third act of a divine comedy. “Behold!” he proclaims to his clients, “this sell-off is but a familiar specter, a ghost from the past two years, haunting us with its predictable wails!”
According to a filing with the SEC, the fund liquidated 282,313 shares, a calculated retreat from a venture that had grown increasingly elusive. The average share price for the quarter, now a mere shadow of its former self, rendered the trade’s value at $13,325,174. One might call it a rational decision, though the word “rational” sits uneasily in the presence of hope.
Both digital darlings are wobbling on their tightropes, testing crucial support levels after a market-wide tumble that left everyone’s knickers in a twist. 🎢
On November 14, 2025, Bain Capital Life Sciences Investors, LLC offloaded 122,106 shares of Pharvaris. The post-sale holding is now 3,181,275 shares, valued at $79.37 million. A quarter-over-quarter increase, mind you, despite the sale. It’s like buying a coffee, then selling it for a bit more-only with stock. My brain hurts just thinking about it.